title: Pregnancy can be established in superovulated adult rats treated with progesterone and an aromatase inhibitor.
abstract: An adult superovulated rat model has been developed and is characterized by high ovulation rates, early morphological degeneration of embryos, complete embryo loss within 48 hours of conception and elevated peripheral estradiol(E2)/progesterone(P4) ratios. In this study, three trials were conducted using the superovulated adult rat model. First, control naturally cycling rats were compared with superovulated rats supplemented with 1 mg P4 on days 0-3 of pregnancy. A sperm positive vaginal smear is designated as day 0 of pregnancy. The P4 treated rats demonstrated improved embryo retrieval on day 1 of pregnancy, continued embryo recovery with a decrease in normal morphologic characteristics of integrity on day 2, with nearly total embryo loss by day 3. On each day, P4 levels were elevated 2-3 times over control. The second trial compared 3 groups of rats, 1) naturally cycling, 2) superovulated unsupplemented and 3) superovulated rats supplemented with 1 mg P4/rat/day and the aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA), 12.5 mg/rat/day. The superovulated unsupplemented rats had no embryo recovery after day 2 of pregnancy, while the P4 and 4-OHA treated rats showed a variable ability to maintain normally developing embryos through day 4 of pregnancy. E2 levels were elevated in both superovulated groups on days 1-4 of pregnancy as were P4 levels on days 2-4. The E2/P4 ratio was significantly lowered only on day 1 of pregnancy in the P4 and 4-OHA treated group. The third trial demonstrated implantation in 50% of the superovulated rats supplemented with P4 and 4-OHA. In conclusion, implantation in the superovulated adult rats can occur with P4 and 4-OHA supplementation, however, this biologic phenomenon could not be explained by obvious changes in peripheral E2 and P4 levels.
authors.affiliation: Department of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus 43210-1092.
authors.forename: R A
authors.initials: RA
authors.lastname: Hayes
authors.forename: K
authors.initials: K
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Akira
authors.forename: Y C
authors.initials: YC
authors.lastname: Lin
authors.forename: C I
authors.initials: CI
authors.lastname: Friedman
authors.forename: M H
authors.initials: MH
authors.lastname: Kim
mesh_terms: D000704:Analysis of Variance; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D047072:Aromatase Inhibitors; D010064:Embryo Implantation / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D005260:Female; D011247:Pregnancy; D011255:Pregnancy Maintenance / Q000187:drug effects; D011270:Pregnancy, Animal / Q000097:blood / Q000187:drug effects*; D011374:Progesterone / Q000097:blood / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013480:Superovulation / Q000502:physiology*
chemical_list: D047072:Aromatase Inhibitors; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; C014594:formestane